Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology (Agonist/TLS) and Autoimmune (Antagonist/Decoy) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LTBR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LTBR ECD-Fc Fusion Protein HEK293 Expressed, Native Glycosylation. Sequence Verified, High Purity (>95%), Endotoxin <1EU/µg. Theoretical MW confirmed. |
View LTBR Products |
| Gene Delivery | LTBR Lentivirus Premade Particles Full-length ORF with puromycin selection for stable cell line construction. |
View LTBR Products |
| Benchmark Ab | Anti-LTBR Benchmark Antibody (Agonist / Antagonist) Recombinant positive controls for both agonistic and blocking modalities. |
View LTBR Products |
| Validator | LTBR siRNA Set (3 specific duplexes) For knockdown verification and specificity controls. |
View LTBR Products |
| Ligand – LIGHT (TNFSF14) | Endogenous activating ligand; alternative ligand for competitive binding. | View TNFSF14 Products |
| Ligand – LTA | Lymphotoxin-alpha, heterotrimer component of LTα1β2. | View LTA Products |
| Pathway Component | TNFSF3 (LTB) Essential subunit of the LTα1β2 heterotrimeric ligand. |
View TNFSF3 Products |
| Off-Target Control | TNFRSF14 (HVEM) Related TNFRSF member for cross-reactivity screening. |
View TNFRSF14 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Agonist Receptor Clustering (Oncology) | High-purity ECD-Fc with Native Glycosylation (HEK293) for reproducible clustering assays. |
| Antagonist Blockade of LTα1β2 Binding (Autoimmune) | High-purity LTBR ECD-Fc validated for complex binding; compatible with SPR and ELISA-based heterotrimer capture. |
| Cross-species Preclinical Evaluation (Human/Cyno/Mouse) | Human, Cyno, and Mouse LTBR ECD proteins available; Sequence Verified for ortholog binding pocket homology. |
| Avoiding Receptor Agonism (Safety Liability) | Epitope-mapped benchmark antibodies available; TRAF-binding deficient mutants as negative controls. |
| Lack of Controls | Clinical Benchmark Antibodies (agonistic & antagonistic) included; validated siRNA for specificity checks. |
| TNFR Superfamily Off-target Screening | Homolog panel proteins (TNFR1, TNFR2, HVEM, CD40) strictly verified by mass spec for selectivity assays. |
| Heterotrimeric Ligand Engagement (LTα1β2 Complex Formation) | High-purity LTBR ECD-Fc validated for complex binding; compatible with SPR and ELISA. |
Live LTBR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LTBR therapeutics is intensifying across two major axes. In oncology, the focus is shifting from traditional antagonists to agonistic antibodies that induce Tertiary Lymphoid Structures (TLS) to convert "cold" tumors "hot" and enhance checkpoint inhibitor efficacy. In autoimmune diseases (e.g., Sjögren's syndrome, SLE), the trend moves from conventional mAbs toward engineered decoy receptors and bispecific antagonists that disrupt lymphoid neogenesis and pathogenic stromal cell activation. The emerging paradigm combines LTBR blockade with BAFF/APRIL pathway modulation for comprehensive autoantibody suppression. First-generation therapies are reaching the clinic, but next-wave R&D demands tumor-microenvironment-specific activation (oncology) or high-affinity ligand trapping (autoimmune) to minimize systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic mAb | Biogen, Roche | Solid Tumors | NF-κB Reporter Assays (Need HEK293 expressed active proteins) |
| Antagonist mAb | Roche/Genentech, Biogen | Sjögren's Syndrome, SLE | Blockade of LTα1β2 binding (Need high-purity ECD-Fc for competition assays) |
| Bispecific Antibody | Emerging Biotechs | Immuno-Oncology, Lymphoid Cancers | Heterodimer validation and dual-target binding (Need High-Purity ECD and cross-reactive Abs) |
| ADC | Specialized Oncology | Lymphoma | Internalization Assay (Need stable cell lines via Lentivirus) |
| Decoy Receptor (Fc-Fusion) | Academic/Preclinical | Rheumatoid Arthritis | Ligand trapping efficiency (Need multimeric LTBR ECD) |
| Fusion Protein (Ligand Blocking) | Various | Autoimmunity | Ligand blocking assay (Need pure TNFSF14/LTA) |
Key Mutation & Biomarker
A notable germline missense variant in LTBR is dbSNP:rs35681405 (UniProt VAR_052346). This mutation may affect receptor-ligand interaction and could serve as a stratification biomarker in clinical trials. TarMart provides mutant protein variants for functional validation.